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All-trans retinoic acid (ATRA) has been studied for the treatment of cancer, including leukemia and 
breast cancer. This work aims to develop nanoemulsions (NE) loaded with a hydrophobic ion pair (HIP) 
of all-trans retinoic acid (ATRA) and a lipophilic amine, stearylamine (SA), and coated with hyaluronic 
acid (HA) to enhance anticancer activity and reducing toxicity. Blank NE was prepared by spontaneous 
emulsification and optimized prior to HIP incorporation. NE-ATRA was electrostatically coated with 
different concentrations of HA. Incorporation of ATRA-SA led to monodisperse NE with small size (129 
± 2 nm; IP 0.18 ± 0.005) and positive zeta potential (35.7 ± 1.0 mV). After coating with 0.5 mg/mL HA 
solution, the mean diameter slightly increased to 158 ± 5 nm and zeta potential became negative (-19.7 ± 
1.2 mV). As expected, high encapsulation efficiency (near 100%) was obtained, confirmed by polarized 
light microscopy and infrared analysis. Formulations remained stable over 60 days and release of ATRA 
from NE was delayed after the hydrophilic HA-coating. HA-coated NE-ATRA was more cytotoxic than 
free ATRA for MDA-MB-231 and MCF-7 breast cancer cell lines, especially in the CD44 overexpressing 
cells. Blank coated formulations showed no cytotoxicity. These findings suggest that this easily-made 
HA-coated NE-ATRA formulation is a promising alternative for parenteral administration, thus improving 
the breast cancer therapy with this drug.
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INTRODUCTION
All-trans retinoic acid (ATRA) is an important 
vitamin A derivative, which plays an anticancer role by 
binding to the nuclear receptors, retinoic acid receptors 
(RAR), and retinoid X receptors (RXR). ATRA regulates 
a variety of genes involved in cell proliferation and 
differentiation (Di Masi et al., 2015), and promotes cell 
proliferation inhibition and apoptosis by arresting the cell 
cycle in the G1 phase (Tang, Gudas, 2011). ATRA has 
been mainly used as a differentiation agent for treatment 
of leukemia, especially acute promyelocytic leukemia 
(Petrie, Zelent, Waxman, 2009), but is also effective 
against other types of cancer such as melanoma, liver, and 
breast carcinomas.
ATRA biodisponibility is low and quite variable 
when orally administered, which is associated with its low 
aqueous solubility (log P = 4.6, <1 mg/mL) (Adamson et 
al., 1993; Abdulmajed, Heard, 2004). This has limited the 
choice of a proper solvent for intravenous administration 
of ATRA. On the other hand, prolonged oral treatment 
with ATRA leads to a progressive decrease in drug 
plasmatic concentrations due to induced metabolism via 
the cytochrome P450 system (Muindi et al., 1992). All 
these factors have limited the clinical use of both oral and 
intravenous ATRA formulations. An alternative to enabling 
the development of intravenous formulations has been the 
incorporation of ATRA in lipid nanostructured systems 
such as nanoemulsions (NE), solid lipid nanoparticles 
(SLN), nanostructured lipid carriers, or liposomes (Hwang 
et al., 2004; Lim, Lee, Kim 2004; Chansri et al., 2006; 
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Kawakami et al., 2006; Carneiro et al., 2012; Silva et al., 
2015).
Despite its lipophilicity, encapsulation of ATRA in 
lipid systems such as SLN is usually low (Jenning, Gohla, 
2001) unless a high surfactant/lipid ratio is used (Lim, 
Kim, 2002; Hu, Tang, Cui 2004). Our group has previously 
reported that the in situ formation of hydrophobic ion pairs 
(HIP) of ATRA and lipophilic amines such as stearylamine 
(SA), benethamine, and maprotiline can significantly 
increase the ATRA incorporation within the lipid matrix 
(Castro et al., 2009; Carneiro et al., 2012; Silva et al., 
2015; Silva et al., 2016). 
Nanoparticles have been found to accumulate in 
tumor sites after intravenous administration due to the 
tumor architecture, which involves fenestrations in the 
endothelium and absence of effective lymphatic drainage 
(Torchilin, 2011). However, this enhanced permeation 
and retention effect does not assure tumor penetration by 
all types of nanosystems, so drugs can be released before 
the nanocarriers are taken up by the cancer cells, resulting 
in therapeutic inefficacy. Considering that the target of 
ATRA is the nuclear receptors, its intracellular delivery 
is important to attain an enhanced therapeutic effect for 
cancer.
Hyaluronic acid (HA) has been utilized in the active 
targeting of nanoparticles to tumors due to its ability to 
specifically bind to CD44 receptors (Mattheolabakis et 
al., 2015) overexpressed in some cancer cells. Therefore, 
the main advantages of coating nanoparticles with HA 
are the selective targeting and long blood circulation 
resulting from the hydrophilic surface comprising HA 
(Almalik, Day, Tirelli, 2013; Tran et al., 2014). Also, HA 
has the advantages of being biocompatible, biodegradable, 
and non-immunogenic, which makes it a good ligand to 
be used in the coating of nanocarriers for drug delivery 
applications (Rivkin et al., 2010; Sun et al., 2012). Thus, 
the main goal of this work was to develop an innovative 
formulation of NE loaded with ATRA and coated with 
HA as an alternative to improve the cancer therapy. 
The in situ formation of HIP was utilized to enhance 
ATRA encapsulation along the experimental design of 
the formulations. In addition, in vitro cytotoxicity was 
investigated against breast cancer cells.
MATERIALS AND METHODS
Materials
ATRA was kindly provided by BASF (Ludwigshafen, 
Germany); Super Refined Tween 80TM (Polysorbate 80) 
and CrodamolTM GTCC (medium chain triglycerides 
[MCT]; caprylic/capric triglycerides) were provided 
by Croda Inc (Edison, NJ, USA). Stearylamine (SA; 
octadecylamine) and egg-lecithin (Lipoid® E80) were 
acquired from Sigma-Aldrich (St Louis, MO, USA) and 
Lipoid (Ludwigshafen, Germany), respectively. HA (MW 
350 kDa) was purchased from All Chemistry (São Paulo, 
SP, Brazil). 
For the in vitro studies, Dulbecco’s modified 
Eagle’s medium was obtained from Sigma-Aldrich 
(St Louis, MO, USA). Fetal bovine serum (FBS) and 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT) were purchased from Life Technologies 
(Carlsbad, CA, USA). The following cancer cell lines 
were used: MCF-7 (human breast adenocarcinoma from 
bone metastasis) and MDA-MB-231 (human breast 
adenocarcinoma, derived from metastatic site) cells 
were acquired from American Type Culture Collection 
(Manassas, VA, USA). All other chemicals were of 
analytical grade.
Preparation and development of NE formulations
NE was prepared by spontaneous emulsification 
(Bouchemal et al., 2004). Compositions of the formulations 
were based on previous studies (Castro et al., 2009; 
Carneiro et al., 2012), but with some modifications. Briefly 
(batch 10 ml), the oily phase (OP), including the organic 
solvent, and the aqueous phase (AP) were weighted and 
prepared separately. When present, ATRA was added in 
the OP. Next, the OP was added dropwise to the AP under 
vigorously magnetic stirring for 10 min. The solvent was 
then removed by evaporation during 60 min under reduced 
pressure (Fisatom, São Paulo, Brasil). The pH of NE was 
adjusted to 7.0 with a 0.01 M HCl solution, using a pH-
meter MS Tecnopon® (mPA 210, Piracicaba, Brazil).
HA coating was performed by electrostatic attraction 
(Yang et al., 2013). Different HA solutions were employed 
to select the ideal concentration for NE coating. In a 
typical procedure, 1 mL of NE dispersion was slowly 
added under vigorous magnetic stirring to a HA solution at 
concentrations of 0.01, 0.25, 0.50, 1.0, 2.0, or 4.0 mg/mL. 
Optimization of the blank NE composition was 
performed by evaluating the influence of surfactant 
combination (Table I) and solvents on the physico-
chemical parameters of NE. Ethanol was utilized in NE 
1-3, while acetone was used in NE 4. The inclusion of a 
sonication stage of 10 min with an ultrasound bath before 
the solvent removal was also evaluated (corresponding 
to NE 5).
After proper optimization of blank formulations, 
0.05% ATRA was utilized to prepare ATRA-loaded NE 
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(ATRA-NE). Finally, ATRA-NE was utilized in the HA 
coating studies performed by electrostatic attraction.
Droplet size analysis and zeta potential
The globule diameter of NE in the dispersion was 
determined by unimodal dynamic light scattering analysis. 
Data were reported as mean globule diameter, evaluated as 
the intensity obtained from three repeated measurements, 
and the polydispersity index. Zeta potential measurements 
were carried out by the dynamic light scattering associated 
with electrophoretic mobility, also in triplicate. All 
determinations were performed using a Zetasizer 3000 
HSA (Malvern Instruments, Malvern, UK), at fixed angles 
of 90° and 25°C. 
Drug encapsulation efficiency
Encapsulation efficiency (EE) for ATRA in NE was 
determined based on quantification of ATRA in the NE 
before (total ATRA) and after filtration (filtered ATRA; 
cellulose ester membrane, 0.45 µm, Millipore, Billerica, 
MA, USA). The fraction of ATRA soluble in the external 
AP of the NE was assessed by ultrafiltration, using a 100 
kDa molecular weight cut-off membrane (Amicon 100 k, 
Millipore, Billerica, MA, USA).
ATRA concentration in NE (before and after 
filtration) or in the AP was determined by the differential 
pulse voltammetry (DPV) method reported by Silva and 
colleagues (Da Silva et al., 2015). Briefly, an aliquot of 
each NE formulation was dissolved in tetrahydrofuran 
and later diluted in a mixture (95:5) of methanol and 0.1 
M acetate buffer (pH 5.0). This dispersion was filtered in a 
0.45 mm Millex HV filter (Millipore, Billerica, MA, USA) 
and analyzed by DPV. EE was then calculated using the 
following formula: EE (%) = (filtered ATRA/total ATRA) 
X 100.
The scan rate and pulse amplitude were 30 mV s−1 and 
75 mV, respectively. The concentration range (9.71 – 45.5 
x 10-6 mol.L-1) used to determine the linear regression 
analysis resulted in the following linear equation: y = 
0.03752x + 0.1717 (R2 = 0.9969).
Stability study
To investigate the influence of the coating on the NE 
stability, HA-ATRA-NE and ATRA-NE were prepared 
in triplicate, kept in 10 mL glass containers filled with a 
nitrogen atmosphere, and stored at 4 °C. Sampling aliquots 
were taken at 7, 15, 30, and 60 days of storage for mean 
diameter, zeta potential, pH, and EE determinations.
Polarized light microscopy
The presence of ATRA crystals was assessed by 
polarized light microscopy (Zeiss Axio Imager.M2, Carl 
Zeiss, Oberkochen, Germany). Undiluted samples were 
placed on microscope slides, and images were acquired 
by utilizing a proper software (ZEN lite 2012, Carl Zeiss, 
Oberkochen, Germany). The microscope was equipped 
with an AxioCam digital camera (Model ERc 5S, Carl 
Zeiss, Oberkochen, Germany).
Infrared analysis
Fourier transform infrared (FTIR) measurements 
were carried out with a Nicolet 6700 spectrometer 
(Thermo Fisher Scientific, Waltham, USA) equipped 
with an attenuated total reflectance (ATR) accessory. 
Spectra were obtained using a Ge crystal in the region 
TABLE I – Composition of NE formulations containing different surfactant systems
Ingredient (% w/v) NE 1 NE 2 NE 3 NE 4* NE 5**
Oily phase
MCT 1.5 1.5 1.5 1.5 1.5
SA 0.1 0.1 0.1 0.1 0.1
Egg lecithin - 0.5 0.5 0.5 0.5
Cholesterol 0.15 0.15 - - -
Aqueous phase
Glycerol 2.25 2.25 2.25 2.25 2.25
Tween® 80 1.0 0.5 0.5 0.5 0.5
Water q.s. 100 100 100 100 100
*NE 4 used acetone rather than ethanol as organic solvent; **NE 5 has the same composition of NE 4, but includes a 10 minutes 
sonication process previously the solvent removal. 
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from 4000 to 700 cm−1 with a resolution of 4 cm-1 and 32 
scan accumulations.
In vitro release studies
The in vitro release behavior of ATRA-NE and 
HA-ATRA-NE was determined in a dissolution medium 
composed of phosphate buffered saline (pH 7.4): ethanol: 
Polysorbate 80 (88:10:2) using a dialysis method (Hu, 
Tang, Cui, 2004; Chinsriwongkul et al., 2012). 2 mL of 
formulation was applied in the dialysis bag with a 14 
kDa cut-off (Sigma-Aldrich, USA). The dialysis bag was 
soaked in an amber flask containing 50 mL of dissolution 
medium under magnetic stirring of 100 rpm. Temperature 
was kept at 37 ± 0.5 °C and all samples were protected 
from light. At time intervals of 30 minutes, 1, 2, 4, 8, and 
24 hours, 1 mL aliquot of the medium was taken, and the 
same volume of fresh medium was added. The amount of 
ATRA released to the medium at each time was quantified 
by DPV. All experiments were performed in triplicate.
Cell cultures
Cytotoxicity studies were conducted on cancer 
cells. Metastatic human breast adenocarcinoma cell 
lines (MCF-7 and MDA-MB-231) were cultivated 
in Dulbecco’s modified Eagle’s medium (DMEM) 
containing 10% FBS, 200 mM glutamine, and antibiotics 
(100 μg ml −1 streptomycin and 100 UI ml−1 penicillin). 
All cultures were kept in a humidified incubator with 5% 
CO2 at 37 °C.
Analysis of cell viability
Cell proliferation was measured by MTT assay 
as previously reported (Carneiro et al., 2012; Silva et 
al., 2015). First, 2.5 × 104 (MCF-7) or 2.0 × 104 (MDA-
MB-231) cells mL−1 were seeded into 96-well plates. After 
24 h of incubation at 37°C and 5% CO2, freshly prepared 
solutions of free ATRA and ATRA-loaded NE were added 
to the wells (ATRA concentration ranging from 1.56 μM 
to 100 μM). Free ATRA was dissolved in absolute ethanol 
(4 mM) before dilution. Non-coated and HA-coated blank 
NE (without ATRA) were diluted in the same way as 
ATRA-loaded NE. After 48 h of incubation at 37 °C and 
5% CO2, 20 μL of 5 mg/mL MTT solution was added to 
each plate. Plates were incubated at 37 °C for 4 h and the 
medium was then replaced by 200 μL of 0.04 mol L−1 HCl 
solution in isopropanol. Cellular viability was estimated 
by measuring the rate of mitochondrial reduction of MTT 
into formazan of each treatment, determined by measuring 
the absorbance of the converted dye at a wavelength of 
595 nm, and compared with cells maintained in medium 
only (100% of viability). Cell viability was found to be 
100% after treatment with negative control (2.5% ethanol). 
Data were expressed as percentage of cell viability in 
relation to the control (mean ± SD) for three independent 
experiments performed in sextuplicate.
Data analysis
Statistical analyses were carried out using one-way 
analysis of variance followed by Tukey’s test. Differences 
among mean values were statistically significant when 
P value was less than 0.05. The statistical software used 
was GraphPad Prism 5.0 (Graphpad Software Inc., San 
Diego, USA).
RESULTS AND DISCUSSION
Development of ATRA-NE formulations
Blank NEs were developed and optimized by the 
spontaneous emulsification method. The physico-chemical 
parameters of the NE 1-5 including mean diameter, 
PDI, and zeta potential are summarized in Table II. 
Initially, the optimization of blank NE was investigated 
by evaluating the influence of surfactants on the globule 
size, PDI, and zeta potential. The presence of micrometric 
droplets increases the risk of embolism and the instability 
of NE, which is manifested by droplet coalescence. 
Thus, emulsions with monodisperse globules with size 
around 200-500 nm tend to be more stable and safer for 
intravenous administration (Hippalgaonkar, Majumdar, 
Kansara, 2010). Combination between polysorbate 80 
and egg lecithin (NE 2, 346 ± 15 nm) caused a significant 
decrease in size when compared with their isolated use 
(NE 1, 422 ± 9 nm); both formulations were found to 
be monodisperse. The influence of cholesterol, a co-
surfactant, was further investigated. Thus, NE 3 was 
prepared without cholesterol and again a significant 
decrease in the size was observed (NE 3, 280 ± 1 nm). 
It is well known that globule size and PDI are 
strongly affected by the nature of the solvent used in the 
spontaneous emulsification process (Bouchemal et al., 
2004). Then, ethanol was replaced by acetone in NE 4, 
but due to the considerable increase in the size (424 ± 
14 nm) and the high PDI (0.42 ± 0.049), and considering 
avoidance of potential toxic effects, ethanol was chosen 
as solvent of NE. Finally, NE 5 was prepared with the 
same composition and solvent of NE 3, but with a final 
stage of 10 minutes bath sonication, and a lower mean 
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diameter (135 ± 2 nm) and PDI (0.17 ± 0.016) were 
observed. Based on these findings, NE 5 was selected for 
the ATRA encapsulation studies. All blank formulations 
exhibited positive zeta potential due to the use of a cationic 
primary amine (SA) which remains at the interface of the 
NE globules. This positive charge is important to enable 
electrostatic attraction in the development of HA-coated 
NE formulations.
After  ATRA incorporat ion (ATRA-NE),  a 
significant decrease in mean particle size (129 ± 2 nm) 
and a monodisperse distribution (PDI 0.18 ± 0.005) were 
observed in comparison with the correspondent blank 
formulation (NE 5), as seen in Table II. Zeta potential 
was also properly positive (35.7 ± 1.0 mV). As expected, 
high EE (96.7 ± 4.9%) was obtained, which is in good 
agreement with our previous work involving incorporation 
of HIP between ATRA and lipophilic amines in lipid 
nanocarriers. ATRA concentration in the AP was found 
to be negligible as previously reported (Carneiro et al., 
2012; Da Silva et al., 2015; Silva et al., 2015; Silva et al., 
2016). The high ATRA retention in lipid matrix is related 
to the hydrophobicity of the counterion used in the HIP 
strategy, while the lipophilic amine is associated with 
intense interaction of ATRA with the lipid matrix (Oliveira 
et al., 2017). In this case, this formulation was considered 
suitable for the coating studies.
To determine the adequate HA concentration for NE 
coating, six HA concentrations from 0.10 to 4.0 mg/mL 
were tested. Considering that pH over the coating process 
was 7.0, both remaining SA (i.e., SA in excess, not in the 
ion pair with ATRA) and HA were ionized (pka of 10.21 
and 4.36, respectively), which favored establishment of 
electrostatic interaction. As can be observed in Figure 
1A, the increase of HA concentration led to a progressive 
increase in size and PDI, which can be explained by 
the coating deposition externally to the globules. Zeta 
potential was progressively reduced (Figure 1B), most 
likely due to the addition of the anionic HA molecules. 
The same reduction in zeta potential was observed by 
other reports (Yang et al., 2013; Tran et al., 2014) in the 
coating process with HA of paclitaxel and vorinostat lipid 
nanocarriers, respectively.
It was not possible to determine the physico-
chemical characteristics of HA-ATRA-NE coated with 
0.25 mg/mL HA solution, since agglomeration was 
observed. The critical step in the electrostatic attraction 
coating process is the inversion of zeta potential, which 
indicates that the coating was successfully performed 
(Almalik, Day, Tirelli, 2013). However, it is possible 
for particle agglomeration to occur when its total charge 
becomes neutral. 
The formulation selected for the further studies was 
HA-ATRA-NE coated by 0.5 mg/mL HA, which presented 
the combination of small monodisperse globule size (158 ± 
5 nm) and negative zeta potential (-19.7 ± 1.2 mV), suitable 
for the parenteral administration. Negative zeta potential 
is important to be achieved, since increased cytotoxicity 
is associated with positively charged nanoparticles and 
their interactions with the negatively charged cellular 
membrane (Lappalainen et al., 1994; Scholer et al., 2001; 
Carneiro et al., 2012). 
In addition, ATRA kept its high encapsulation in the 
HA-coated NE (99.2 ± 0.5%), as can be seen in Figure 2. 
Likewise, drug loading remained unchanged (1.9% before 
and after the coating process). The concentration of ATRA 
was again found to be negligible in the AP. The presence 
of insoluble ATRA crystals in the external aqueous phase 
of ATRA-NE and HA-ATRA-NE was evaluated by 
polarized light microscopy in order to confirm the high 
EE. The obtained images are also shown in Figure 2, 
revealing that there were no ATRA crystals in the AP of 
both formulations, as expected (Carneiro et al., 2012; Silva 
et al., 2015; Silva et al., 2016).
Infrared analysis
HA-coated and non-coated formulations were 
FIGURE 1 – Influence of HA concentration in mean globule 
diameter and PDI (A) and in zeta potential (B) of ATRA-loaded 
NE in the coating process.
L. M. S. Tinoco, F. L. O. Silva, L. A. M. Ferreira, E. A. Leite, G. Carneiro
Braz. J. Pharm. Sci. 2018;54(4):e17361Page 6 / 10
also investigated by ATR-FTIR (Figure 3) to confirm 
the coating process. Observed in the HA-ATRA-NE, 
in comparison with ATRA-NE, was a clear increase 
in the intensity of the band in 1745 cm-1 ascribed to 
carboxylic acid C=O stretching mode and bands at 
2850 and 2900 cm-1, related to C-H stretching modes, 
suggesting the insertion of HA in the NE (Lopes et al., 
2014). Corroborating with size and zeta potential data, 
FTIR results may provide additional evidence of the 
electrostatic attraction between the excess amine and 
the carboxylic group of HA, thus allowing coating of the 
globules (Tran et al., 2014).
Stability studies
After 60 days of storage in a refrigerator, no 
significant alteration in size was found for ATRA-NE 
(Figure 4A), which was 169 ± 0.6 nm after 60 days. PDI 
increased slightly, but the formulation was still considered 
monodisperse. HA-ATRA-NE had a significant increase 
in size from 140 ± 2 to 189 ± 3 nm after 15 days storage, 
but remained constant up to 60 days (Figure 4B). 
Zeta potential of both positively charged ATRA-NE 
and negatively charged HA-ATRA-NE remained constant 
over 60 days (Figure 4C). In addition, ATRA remained 
highly encapsulated in both coated and non-coated NE (EE 
were 96.5 ± 1.0 and 96.3 ± 0.6 %, respectively, after 60 
days). Finally, no presence of yellow crystals was observed 
at the external aqueous phase of both NE, indicating the 
high ATRA encapsulation over time. 
In vitro drug release
Release profiles of ATRA from HA-coated and non-
coated NE, and diffusion from ATRA solution are shown 
in Figure 5. In the same dissolution medium, the diffusion 
rate of ATRA solution was faster than that of the NE 
formulations. After 24 hours, 96.5 ± 1.5% of free ATRA 
had already diffused against 90.1 ± 1.1 % (ATRA-NE) and 
75.7 ± 1.4 % (HA-ATRA-NE). HA-ATRA-NE released 
ATRA in a significantly slower manner than ATRA-NE 
within 24 hours (P < 0.05), indicating that the external 
hydrophilic HA coating could restrict the diffusion of 
ATRA through the encapsulating layer. 
These results suggest that there is a controlled 
release of ATRA from HA-coated NE. In solution, drug 
release is a simple diffusion process from the dialysis bag 
to the receptor fluid; however, when encapsulated in a 
nanostructure, a mechanism that is slower to release the 
drug from the nanostructure core is usually needed, such 
as erosion, disintegration, or desorption (Rahman et al., 
2013).
TABLE II – Physicochemical characterization of NE formulations
NE Diameter (nm) PDI
Zeta Potential 
(mV)
1 422 ± 9 0.18 ± 0.006 (+) 10.8 ± 1.3
2 346 ± 15 0.22 ± 0.007 (+) 30.4 ± 0.8
3 280 ± 1 0.19 ± 0.003 (+) 29.9 ± 1.1
4 424 ± 14 0.42 ± 0.049 (+) 36.1 ± 1.1
5 135 ± 2 0.17 ± 0.016 (+) 40.9 ± 1.2
ATRA-NE 129 ± 2 0.18 ± 0.005 (+) 35.7 ± 1.0
Data represented as mean ± SD (n = 3)
FIGURE 2 – Influence of HA coating on the encapsulation 
efficiency for ATRA in NE formulations. Data are shown as 
mean ± SD. n = 3. Rare ATRA microcrystals can be observed 
in the external phase of NE. indicating high encapsulation 
(Polarized Light Microscopy images. 40× magnification).
FIGURE 3 – FTIR-ATR spectra of ATRA, HA, coated and non-
coated ATRA-loaded NE.
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Cell viability studies
Breast cancer cell lines (MCF-7 and MBA-MB-231) 
were used to determine the cytotoxic activity of free 
ATRA or ATRA incorporated in the chosen HA-coated 
NE formulation. The cells were incubated with free ATRA 
or HA-ATRA-NE and analyzed with respect to their 
viability as shown in Figure 6. Cell viability was found to 
be 100% after treatment with negative control, and blank 
HA-coated formulations exhibited little cytotoxicity (over 
80% viability).
In all cell lines, there was a clear response to the 
treatment with free ATRA and the decrease in the cell 
viability was dose dependent, with a reduction from 
100% at 1.56 µM to 81 ± 5.2% (MCF-7) and 86 ± 2.1% at 
50 µM (MDA-MB-231), which are comparable to values 
obtained in previous studies (Fanjul et al., 1996; Hong, 
Lee-Kim, 2009). 
Cytotoxic activity of ATRA incorporated in HA-
coated NE on both cell lines was more pronounced than 
that of free ATRA. Cell viability was 33 ± 2.8% in MCF-
7 cells and 24 ± 1.6% in MDA-MB-231 cells at 50 µM. 
This effect could be associated with the lipophilic nature 
of the nanocarrier and enhanced intracellular absorption 
by CD44 receptor mediated endocytosis (Ramasamy et 
al., 2014; Tran et al., 2014). In addition, higher activity is 
expected for MDA-MB-231 cell lines, which is directly 
associated with CD44 receptor expression. Since MCF-7 
cells express low levels of CD44 receptor (Tran et al., 
2014), uptake of HA-coated NE would be lower when 
compared to MDA-MB-231 cells, with higher levels 
of CD44 expression. It is well-known that cationic SA 
formulations show cytotoxic effects associated with 
electrostatic interactions between the highly positive 
charged nanocarriers and anionic phospholipids of the 
FIGURE 4 – Stability of mean diameter and PDI of ATRA-NE (A) and HA-ATRA-NE (B). Zeta potential (C) and encapsulation 
efficiency (D) of ATRA in NE. Data represented as mean ± SD (n = 3).
FIGURE 5 – Cumulative ATRA release from NE compared to a 
solution at 37 ± 0.5 °C.
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cell membrane, leading to damage of the latter (Roberts, 
Addy, 1981; Lappalainen et al., 1994; Scholer et al., 2001; 
Yang et al., 2013). In fact, this unspecific cytotoxicity was 
observed for unloaded SLN containing SA against cancer 
and normal cell lines (Lappalainen et al., 1994; Carneiro 
et al., 2012), which is not the case for blank HA-coated 
NE formulations.
CONCLUSION
A formulation of NE loaded with ATRA and coated 
with hyaluronic acid was developed with reduced size, 
negative zeta potential, and high encapsulation. This 
formulation was suitable for intravenous administration 
and remained stable over 60 days. ATRA was released 
more slowly from HA-coated NE compared to non-coated 
formulations, because of the additional hydrophilic layer 
of HA. HA-ATRA-NE was more cytotoxic against breast 
cancer cell lines than free ATRA, especially against cells 
overexpressing CD44.
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